Articles Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase
A randomized, placebo-controlled, phase 3 study of masitinib for treatment of severely symptomatic indolent systemic mastocytosi
A randomized, placebo-controlled, phase 3 study of masitinib for treatment of severely symptomatic indolent systemic mastocytosi
![Lawrence z Afghánistánu Datum: Autor: Jakub Horák Zdroj: ego! Rubrika: Reportáž Strana: 14 - PDF Stažení zdarma Lawrence z Afghánistánu Datum: Autor: Jakub Horák Zdroj: ego! Rubrika: Reportáž Strana: 14 - PDF Stažení zdarma](https://docplayer.cz/docs-images/47/21221921/images/page_4.jpg)